HealthHIV prevention drug hailed as breakthrough, but who gets access?
Lenacapavir, injected twice a year, could transform HIV prevention after a trial in South Africa and Uganda recorded no infections among recipients. The WHO recommends it as an additional PrEP option, but high prices, licensing rules and supply arrangements may leave many low- and middle-income countries without affordable generics until 2027.
AAl Jazeera★★★★☆2026-10-01 13:54Original
HIV prevention drug hailed as breakthrough, but who gets access?
Health